News
OHE’s Adrian Towse to Take Office as ISPOR President
3 June 2014
The challenge of globalisation heads Towse’s list of four core targets for ISPOR. OHE’s Director, Adrian Towse, is President of the International Society for Pharmacoeconomics and…
Orphan Drugs Policies: A Suitable Case for Treatment
20 May 2014
Towse and Drummond take a critical look at deficiencies in policy and suggest revisions. An editorial just published by OHE’s Adrian Towse and Michael Drummond of…
The Expanding Value Footprint of Oncology Treatments
13 May 2014
A new OHE Consulting Report examines the importance and history of HTA evaluations for additional uses for cancer drugs after their initial approval. The potential value…
2014 Annual Lecture: Is Universal Health Care Coverage the Holy Grail?
7 May 2014
Join us on the evening of 9 June 2014 when OHE will welcome Professor Anne Mills of the London School of Hygiene and Tropical Medicine who…
Innovation in Oncology: Real Option Value and Path Dependence
29 April 2014
Real Option Value and Path Dependence in Oncology Innovation. Based on an OHE Lunchtime Seminar, this Seminar Briefing addresses a persistent issue: how to adequately reward…
How Will Demands for Effectiveness Evidence Change Drug Development?
23 April 2014
Interviews with 19 senior pharma execs suggest how and to what extent effectiveness research may be integrated into drug development. Changes in the clinical and economic…
Biosimilars and HTA: Results of a Roundtable Discussion
9 April 2014
Experts from the three UK HTA agencies, the MHRA, and academia discussed which HTA methods are most appropriate for biosimilars in specific situations. OHE convened a…
Use of Cost-effectiveness Evidence in US Health Care: Seminar Briefing
1 April 2014
Just published by OHE, this Seminar Briefing summarises remarks at an OHE Lunchtime Seminar by Dr James Chambers of the Center for the Evaluation of Value…
OHE Models Incentives for Antibiotic Drug Development
18 March 2014
The OHE model takes into account the value to society of new antibiotics as well as the risks and rewards for payers and the entities developing…